HPLC method development and validation for the estimation of axitinibe in rabbit plasma
DOI:
https://doi.org/10.1590/s2175-97902017000300012Keywords:
High performance liquid chromatography/method validation, Axitinibe/determination, Axitinibe/ kidney cancer treatment, Crizotinibe, Rabbit plasma, Tyrosine kinase inhibitorAbstract
A rapid, sensitive, and accurate high performance liquid chromatography for the determination of axitinibe (AN) in rabbit plasma is developed using crizotinibe as an internal standard (IS). Axitinibe is a tyrosine kinase inhibitor, used in the treatment of advanced kidney cancer, which works by slowing or stopping the growth of cancer cells. The chromatographic separation was performed on a Waters 2695, Kromosil (150 mm × 4.6 mm, 5 µm) column using a mobile phase containing buffer (pH 4.6) and acetonitrile in the ratio of 65:35 v/v with a flow rate of1 mL/min. The analyte and internal standard were extracted using liquid-liquid extraction with acetonitrile. The elution was detected by photo diode array detector at 320 nm.The total chromatographic runtime is 10.0 min with a retention time for axitinibe and IS of 5.685, and 3.606 min, respectively. The method was validated over a dynamic linear range of 0.002-0.2µg/mL for axitinibe with a correlation coefficient of r2 0.999.Downloads
Download data is not yet available.
Downloads
Published
2017-01-01
Issue
Section
Articles
License
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
How to Cite
HPLC method development and validation for the estimation of axitinibe in rabbit plasma. (2017). Brazilian Journal of Pharmaceutical Sciences, 53(3), e00012-. https://doi.org/10.1590/s2175-97902017000300012